Inovio Pharmaceuticals, Inc. (NYSE: INO) reported Q2 EPS of ($0.02), $0.03 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $1.79 million.

Earnings